CN103709234B - Fviii 肽和它们用于耐受化血友病患者的用途 - Google Patents

Fviii 肽和它们用于耐受化血友病患者的用途 Download PDF

Info

Publication number
CN103709234B
CN103709234B CN201310392152.6A CN201310392152A CN103709234B CN 103709234 B CN103709234 B CN 103709234B CN 201310392152 A CN201310392152 A CN 201310392152A CN 103709234 B CN103709234 B CN 103709234B
Authority
CN
China
Prior art keywords
peptides
peptide
fviii
hemophilia
factor viii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201310392152.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN103709234A (zh
Inventor
戴维.赖思
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baimingxinkang Biotechnology Zhejiang Co ltd
Original Assignee
Hasselt Universiteit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hasselt Universiteit filed Critical Hasselt Universiteit
Publication of CN103709234A publication Critical patent/CN103709234A/zh
Application granted granted Critical
Publication of CN103709234B publication Critical patent/CN103709234B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201310392152.6A 2007-12-04 2008-12-03 Fviii 肽和它们用于耐受化血友病患者的用途 Expired - Fee Related CN103709234B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0723712.6 2007-12-04
GBGB0723712.6A GB0723712D0 (en) 2007-12-04 2007-12-04 Peptides
CN200880119313.1A CN101889024B (zh) 2007-12-04 2008-12-03 Fviii肽和它们用于耐受化血友病患者的用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN200880119313.1A Division CN101889024B (zh) 2007-12-04 2008-12-03 Fviii肽和它们用于耐受化血友病患者的用途

Publications (2)

Publication Number Publication Date
CN103709234A CN103709234A (zh) 2014-04-09
CN103709234B true CN103709234B (zh) 2017-01-18

Family

ID=38982965

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201310392152.6A Expired - Fee Related CN103709234B (zh) 2007-12-04 2008-12-03 Fviii 肽和它们用于耐受化血友病患者的用途
CN200880119313.1A Expired - Fee Related CN101889024B (zh) 2007-12-04 2008-12-03 Fviii肽和它们用于耐受化血友病患者的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200880119313.1A Expired - Fee Related CN101889024B (zh) 2007-12-04 2008-12-03 Fviii肽和它们用于耐受化血友病患者的用途

Country Status (25)

Country Link
US (1) US8445448B2 (enExample)
EP (1) EP2227488B3 (enExample)
JP (2) JP5501245B2 (enExample)
KR (1) KR101519840B1 (enExample)
CN (2) CN103709234B (enExample)
AU (1) AU2008332968B2 (enExample)
BR (1) BRPI0820143A2 (enExample)
CA (2) CA3005013C (enExample)
CY (1) CY1115168T1 (enExample)
DK (1) DK2227488T6 (enExample)
EA (1) EA019370B1 (enExample)
EC (1) ECSP10010327A (enExample)
ES (1) ES2458315T7 (enExample)
GB (1) GB0723712D0 (enExample)
HR (1) HRP20140344T4 (enExample)
IL (1) IL205780A (enExample)
MX (1) MX2010006084A (enExample)
MY (1) MY150995A (enExample)
NZ (1) NZ585217A (enExample)
PL (1) PL2227488T6 (enExample)
PT (1) PT2227488E (enExample)
SI (1) SI2227488T1 (enExample)
UA (1) UA101003C2 (enExample)
WO (1) WO2009071886A1 (enExample)
ZA (1) ZA201002997B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1311542T1 (sl) 2000-08-21 2009-02-28 Apitope Technology Bristol Ltd Tolerogenski peptidi
GB0801513D0 (en) * 2008-01-28 2008-03-05 Circassia Ltd Peptides from factor VIII
SI2300497T1 (sl) * 2008-06-24 2013-02-28 Octapharma Ag Postopek za äťiĺˇäťenje koagulacijskega faktorja viii
GB0908515D0 (en) * 2009-05-18 2009-06-24 Apitope Technology Bristol Ltd Peptide
US20120135917A1 (en) * 2009-06-16 2012-05-31 Eisaku Yoshihara Anti-Gram Negative Bacteria Agent
DK2632479T3 (en) * 2010-10-27 2017-08-07 Baxalta GmbH FVIII PEPTIDES FOR IMMUNT TOLERANCE INDUCTION AND IMMUNODIAGNOSTICS
PL3453402T3 (pl) 2012-01-12 2022-03-21 Bioverativ Therapeutics Inc. Zmniejszenie immunogenności przeciwko czynnikowi viii u osób poddawanych terapii czynnikiem viii
PL2917232T3 (pl) * 2012-11-12 2017-09-29 Apitope International Nv Pochodzące od czynnika VIII peptydy do zastosowania w leczeniu hemofilii A
GB201314052D0 (en) 2013-08-06 2013-09-18 Apitope Int Nv Peptides
WO2017096329A1 (en) 2015-12-03 2017-06-08 Juno Therapeutics, Inc. Modified chimeric receptors and related compositions and methods
BR112019011198A2 (pt) 2016-12-02 2019-12-17 Bioverativ Therapeutics Inc métodos de indução de tolerância imune a fatores de coagulação
US12077607B2 (en) * 2021-09-23 2024-09-03 University Of Utah Research Foundation Functional and therapeutic effects of PAR4 cleavage by cathepsin G

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002060917A2 (en) * 2000-12-01 2002-08-08 Regents Of The University Of Minnesota Method to treat hemophilia

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT94427A (pt) 1989-06-20 1991-03-20 Scripps Clinic Res Processo para a preparacao de polipeptidos que inibem a ligacao de factor viii humano a fosfolipidos
BR9806793A (pt) * 1997-01-22 2000-05-16 Univ Texas Processos e composições de fator tissular para coagulação e tratamento de tumores.
SI1311542T1 (sl) * 2000-08-21 2009-02-28 Apitope Technology Bristol Ltd Tolerogenski peptidi
AU2002233340B2 (en) * 2001-02-19 2008-05-22 Merck Patent Gmbh Artificial fusion proteins with reduced immunogenicity
AU2002312660A1 (en) * 2001-05-31 2002-12-16 D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
JP2005538694A (ja) * 2002-04-18 2005-12-22 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 修飾されたｖｉｉｉ因子
SI1729795T1 (sl) * 2004-02-09 2016-04-29 Human Genome Sciences, Inc. Albuminski fuzijski proteini
WO2006003183A1 (de) 2004-07-02 2006-01-12 Alois Jungbauer Peptide zur blockierung von fviii-inhibitoren
IL229645A0 (en) * 2013-11-26 2014-03-31 Omrix Biopharmaceuticals Ltd A dry bandage containing thrombin and pectin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002060917A2 (en) * 2000-12-01 2002-08-08 Regents Of The University Of Minnesota Method to treat hemophilia

Also Published As

Publication number Publication date
CN103709234A (zh) 2014-04-09
EP2227488A1 (en) 2010-09-15
DK2227488T3 (da) 2014-04-22
PL2227488T6 (pl) 2015-04-30
HRP20140344T1 (en) 2014-05-09
ES2458315T7 (es) 2015-02-18
EA019370B1 (ru) 2014-03-31
HK1144292A1 (en) 2011-02-11
AU2008332968B2 (en) 2014-03-20
ES2458315T3 (es) 2014-04-30
PT2227488E (pt) 2014-04-21
MX2010006084A (es) 2010-06-23
CA3005013C (en) 2021-11-16
DK2227488T6 (en) 2015-02-16
US20100323966A1 (en) 2010-12-23
WO2009071886A1 (en) 2009-06-11
CN101889024A (zh) 2010-11-17
AU2008332968A1 (en) 2009-06-11
EP2227488B1 (en) 2014-01-22
GB0723712D0 (en) 2008-01-16
US8445448B2 (en) 2013-05-21
JP6063402B2 (ja) 2017-01-18
JP5501245B2 (ja) 2014-05-21
HRP20140344T4 (hr) 2015-07-31
UA101003C2 (uk) 2013-02-25
EP2227488B3 (en) 2014-11-19
CY1115168T1 (el) 2016-12-14
ZA201002997B (en) 2011-07-27
BRPI0820143A2 (pt) 2015-05-12
KR20100087346A (ko) 2010-08-04
CA3005013A1 (en) 2009-06-11
KR101519840B1 (ko) 2015-05-18
CA2707559C (en) 2018-07-03
IL205780A0 (en) 2010-11-30
NZ585217A (en) 2012-11-30
MY150995A (en) 2014-03-31
PL2227488T3 (pl) 2014-07-31
IL205780A (en) 2015-06-30
CN101889024B (zh) 2014-04-23
JP2011505414A (ja) 2011-02-24
CA2707559A1 (en) 2009-06-11
JP2014088440A (ja) 2014-05-15
SI2227488T1 (sl) 2014-06-30
EA201070681A1 (ru) 2010-10-29
ECSP10010327A (es) 2010-09-30

Similar Documents

Publication Publication Date Title
CN103709234B (zh) Fviii 肽和它们用于耐受化血友病患者的用途
CN102458445B (zh) Fviii衍生肽
AU2014200237B2 (en) FVIII peptides and their use in tolerising haemophiliacs
HK1172240A (en) Fviii-derived peptides and their use in tolerising haemophiliacs
HK1172240B (en) Fviii-derived peptides and their use in tolerising haemophiliacs
HK1173358B (en) Fviii-derived peptides
HK1144292B (en) Fviii peptides and their use in tolerising haemophiliacs

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20230215

Address after: Room 215, Building 2, No. 198, Peninsula Middle Road, Dipu Street, Anji County, Huzhou City, Zhejiang Province

Patentee after: Baimingxinkang Biotechnology (Zhejiang) Co.,Ltd.

Address before: Belgium Di Pentti Beck

Patentee before: APITOPE INTERNATIONAL N.V.

TR01 Transfer of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170118

CF01 Termination of patent right due to non-payment of annual fee